business
Johnson & Johnson to Acquire Swiss Biotech Firm for $30 Billion
Johnson & Johnson to Acquire Swiss Biotech Firm for $30 Billion
Joshua A. Krisch | Jan 27, 2017
With its purchase of Actelion, Johnson & Johnson’s acquires experimental treatments for pulmonary arterial hypertension and several rare diseases.
That Other CRISPR Patent Dispute
That Other CRISPR Patent Dispute
Kerry Grens | Aug 31, 2016
The Broad Institute and Rockefeller University disagree over which scientists should be named as inventors on certain patents involving the gene-editing technology.
Former Affymetrix Employees Fail to Stop Thermo Fisher Takeover
Former Affymetrix Employees Fail to Stop Thermo Fisher Takeover
Bob Grant | Mar 22, 2016
Their $1.5 billion bid, which topped Thermo Fisher Scientific’s $1.3 billion offer for the genetic analysis company, was rejected.
Thermo Fisher to Acquire Affymetrix
Thermo Fisher to Acquire Affymetrix
Tracy Vence | Jan 11, 2016
The boards of both companies have agreed to a $1.3 billion deal, which is subject to Affymetrix shareholder approval.
Biotech Stocks Take a Hit
Biotech Stocks Take a Hit
Kerry Grens | Sep 30, 2015
Some say the biotech bubble has burst over concerns that drug prices are too high—and may soon be regulated.
Treating Toxoplasmosis
Treating Toxoplasmosis
Jef Akst | Sep 25, 2015
While one company hikes the price of an old drug to treat the parasitic infection, academic researchers report that an approved blood pressure medication could be just what the doctor ordered.
New Scripps Research Institute Leadership
New Scripps Research Institute Leadership
Jef Akst | Sep 20, 2015
The nonprofit institution names a new CEO and president.
Biotech Buys Autoimmune Firm for $7B
Biotech Buys Autoimmune Firm for $7B
Kerry Grens | Jul 16, 2015
Celgene has purchased Receptos, developer of an experimental multiple sclerosis drug.
Celladon Shutters Its R&D
Celladon Shutters Its R&D
Kerry Grens | Jun 26, 2015
Biotech firm likely to pull the plug after its gene therapy product fails.
Another CAR-T IPO
Another CAR-T IPO
Jef Akst | Apr 6, 2015
Cellectis goes public for a whopping $228 million—nearly double the value the company filed for in February.